The objective of this trial is to assess if treatment with basiliximab allows subjects to taper off other immunosuppressive drug regimens without causing an increase in their uveitis.

Inclusion Criteria:

• Diagnosis of noninfectious intermediate, posterior or panuveitis of at least 3 months duration
• Treatment with greater than or equal to 20 mg/day of Prednisone at baseline or immunosuppressive drug score of greater than or equal to 5 at baseline
• BCVA by ETDRS protocol better than or equal to 20/200
• Intraocular pressure of 24 mmHg or less
• Anterior chamber cells and vitreous haze of less than or equal to 1
• Male or females, aged 12 or greater, body weight of 40 kg or greater

Exclusion Criteria:

• Prior treatment with Retisert
• Primary diagnosis of anterior uveitis, uveitis of infectious etiology or Behcet's disease
• Pregnancy or breast-feeding
• Increase in systemic immunosuppressive treatment regimen within 6 weeks before baseline